Keros Therapeutics (NASDAQ:KROS) Posts Earnings Results

Keros Therapeutics (NASDAQ:KROS) issued its quarterly earnings results on Wednesday. The company reported ($1.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.36) by $0.22, Zacks reports. The business had revenue of $3.04 million during the quarter, compared to analysts’ expectations of $37.32 million. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%.

Keros Therapeutics Stock Performance

Shares of NASDAQ KROS opened at $11.03 on Thursday. Keros Therapeutics has a 52-week low of $9.77 and a 52-week high of $73.00. The company’s 50 day moving average price is $12.76 and its 200-day moving average price is $39.99. The company has a market capitalization of $446.83 million, a P/E ratio of -2.13 and a beta of 1.39.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Guggenheim reaffirmed a “neutral” rating on shares of Keros Therapeutics in a research note on Friday, January 17th. Oppenheimer lowered their price target on Keros Therapeutics from $63.00 to $23.00 and set an “outperform” rating for the company in a report on Thursday, January 16th. Jefferies Financial Group started coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating on the stock. HC Wainwright lowered their target price on Keros Therapeutics from $47.00 to $40.00 and set a “buy” rating for the company in a research note on Thursday. Finally, Wedbush downgraded shares of Keros Therapeutics from an “outperform” rating to a “neutral” rating and reduced their price target for the company from $47.00 to $15.00 in a research note on Friday, January 17th. Six equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $51.78.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.